MISSION
Panakes is a venture capital firm with the ultimate goal of providing a better life to people all around the world.
We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences.
We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel.
We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development.
We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor.
We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers.
An overall positive impact that will produce intrinsic value for both investors and society.
TEAM
ADVISORS

SERGIO ABRIGNANI
Scientific Director INGM (Istituto Nazionale di Genetica Molecolare)
ANTONELLO BISCINI
Former VP BizDev Diagnostic Menarini Group

PAOLA CASTAGNOLI
Scientific Director Fondazione Toscana Life Sciences
FABRIZIO CHINES
Executive Chairman & CEO SIFI
VALENTINA COGLIATI
CEO Elemaster
MAURIZIO COLOMBO
Owner & Executive VP Sapiolife
EMANUELE GATTI
Former CEO EMEA Fresenius Medical Care
MASSIMO MERCATI
CEO Aboca
SIMONE RE
CEO Digitec Innovation
LUCIO ROVATI
CEO & Chairman Rottapharm
RAFFAELE VENAFRO
Founder CrossmedPORTFOLIO
NEWS

Milan, Italy, January 30, 2025
Tensive raises €14,000,000 Series A Financing Round led by Panakès Partners SGR to transform breast reconstruction following lumpectomy. Appoints Sanjay Kakkar as Chief Executive Officer

Lymphatica Medtech SA, EPFL Innovation Park Building E, 1015 Lausanne, Switzerland
LYMPHATICA MEDTECH CLOSES € 17.9 M SERIES B FUNDING ROUND TO DRIVE INNOVATION IN LYMPHEDEMA TREATMENT

LIÈGE, Belgium & LAUSANNE, Switzerland, September 13, 2024
SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.
ESG
At Panakes we take the impact of our activities on the environment and on society very seriously. |


Panakes Partners oversees two Alternative Investment Funds (AIFs) classified under Article 6 of the Sustainable Finance Disclosure Regulation (SFDR), namely the Panakes Fund and the Panakes Fund Purple.
Panakes Partners incorporates sustainability risks into the investment decision-making process by evaluating and measuring the Environmental, Social, and Governance (ESG) risks of each investee in accordance with the Risk Management Policy. The Responsible Investment Policy integrates environmental and social characteristics into various investment stages, and a dedicated investment procedure has been established for the Panakes Fund Purple. Since 2022, an annual ESG Report is made available to investors of the Panakes Fund Purple.
Transparency of Adverse Sustainability Effects at the Entity Level (Article 4 of Regulation (EU) 2019/2088):
Due to the size and early-stage nature of the portfolio companies, Panakes is not able to fully and comprehensively assess all negative sustainability impacts with reference to the indicators in Table 1 of Annex I of the Regulatory Technical Standards (RTS). Not all portfolio companies can report their negative impacts, nor is such data available from other sources. Nevertheless, Panakes partially integrates the assessment of the primary negative impacts of investment decisions on sustainability factors whenever possible using the Principal Adverse Impacts (PAIs). Panakes is committed to updating this information based on the adopted approach.